Get the Daily Brief
Latest Biotech News
Evommune files for IPO — raise to fund two Phase‑2 autoimmune drugs
Palo Alto‑based Evommune filed for an initial public offering to fund late‑stage development of two oral or biologic candidates for chronic spontaneous urticaria and atopic dermatitis. The...
Mammoth to trial triglyceride‑lowering gene edit — primate data released
Mammoth Biosciences disclosed first monkey data for its lead in vivo gene editing program aimed at permanently lowering triglycerides, and announced plans for an initial clinical trial. The...
Tempus wins $60.5M ARPA‑H contract — AI diagnostics for precision cancer program
Tempus was awarded a $60.5 million, five‑year contract by ARPA‑H to provide testing and CRO services for the ADAPT precision cancer therapy program. Under the agreement, Tempus will deploy its...
Novo buys Akero: $4.7B bet on FGF21 MASH drug
Novo Nordisk agreed to acquire Akero Therapeutics in a cash deal that pays roughly $4.7 billion up front, with contingent payments that could bring the total to about $5.2 billion. The transaction...
Bristol Myers to buy Orbital for $1.5B — stakes in in vivo CAR‑T
Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion in cash, the company announced, marking a strategic move into in vivo CAR‑T platforms. Orbital is developing in vivo...
FDA approves Jascayd: new oral IPF option for rare lung disease
The U.S. Food and Drug Administration granted approval to Jascayd (nerandomilast), a preferential PDE4B inhibitor developed by Boehringer Ingelheim, for idiopathic pulmonary fibrosis (IPF). The...
Intellia reports in vivo gene‑editing gains — HAE and ATTR progress
Intellia Therapeutics presented clinical updates on its in vivo gene‑editing programs at ESGCT, reporting durable pharmacodynamic effects and safety signals across multiple trials. The company...
AstraZeneca to pay up to $555M — Algen’s CRISPR‑AI target hunt
AstraZeneca struck a multi‑year discovery and option agreement with Algen Biotechnologies valued at up to $555 million. The collaboration pairs AstraZeneca’s R&D muscle in immunology with Algen’s...
Tempus wins $60.5M ARPA‑H contract — to power ADAPT cancer program
Tempus AI was awarded a $60.5 million, five‑year contract by ARPA‑H to provide testing and CRO services for the Advanced Analysis for Precision Cancer Therapy (ADAPT) program. Under the deal...
Parse Biosciences scores patent win — single‑cell IP battle shifts
Parse Biosciences secured a court ruling that invalidated a Scale Biosciences patent now owned by 10x Genomics, removing one asserted claim in ongoing patent litigation. A U.S. District Court...
Consortium publishes pan‑disease blood atlas — 59 conditions profiled in Science
An international consortium released a pan‑disease plasma proteome atlas profiling blood proteins across 59 diseases and multiple cohorts; the work appeared in Science. The project measured...
Mammoth plans first trial: monkey data show durable triglyceride edits
Mammoth Biosciences disclosed nonhuman primate data for its lead in vivo gene‑editing program aimed at lowering triglycerides, and announced plans for a first human trial. The company reported...
Nature maps somatic selection across populations — deep sequencing reveals drivers
A Nature study released population‑scale analyses of somatic mutations and selection across human tissues using ultra‑deep duplex sequencing. The authors combined very high‑coverage sequencing...
Novo buys Akero for $4.7B — adds FGF21 fibrosis candidate
Novo Nordisk agreed to acquire Akero Therapeutics for $4.7 billion in cash to secure efruxifermin, an FGF21 analogue that showed fibrosis reversal signals in a Phase IIb study. The deal transfers...
Pan-disease proteome: SciLifeLab maps blood proteins across 59 diseases
An international consortium led by SciLifeLab and KTH published a large-scale proteomic atlas in Science profiling more than 9,000 blood samples across 59 diseases using Olink’s Explore/Explore HT...
Updated NanoSeq finds pre‑oncogenic somatic variants — cheaper targeted sequencing
Wellcome Sanger researchers released an updated NanoSeq method that adapts duplex sequencing for targeted panels, offering a lower‑cost approach to profile rare somatic variants across hundreds of...
Intellia clinical update: in vivo LNP programs show durable biology
Intellia provided a clinical update on its in‑vivo LNP gene‑editing programs at ESGCT, with CSO Birgit Schultes reporting multi‑year biomarker suppression in some cohorts and sustained...
Tempus wins $60.5M ARPA‑H contract — supplies testing for ADAPT cancer program
Tempus AI secured a $60.5 million, five‑year contract from ARPA‑H to support the ADAPT precision cancer therapy program. Under the award, Tempus will supply genomic and transcriptomic testing (xR...
Court invalidates single‑cell patent — Parse Bio defeats Scale/10x claim
A U.S. district court memorandum held claims in US Patent No. 11,634,752 (owned by Scale Biosciences/10x Genomics) invalid for lack of written description and enablement after Parse Biosciences...
Programmable proteins: Boolean logic gates steer precision drug delivery
Researchers at the University of Washington published a Nature Chemical Biology proof‑of‑principle for 'logic‑programmed' proteins that autonomously present therapeutic cargo only when defined...